Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer
Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer
复制标题
DOI：
10.1016/j.ejca.2006.06.013
复制
发表时间：
2006-11-01
影响因子：
8.4
通讯作者：
Escobedo, Agustin P.
中科院分区：
文献类型：
--
作者：
Arriola, Edurne;Moreno, Abelardo;Escobedo, Agustin P.
目的：研究HER-2和拓扑异构酶II α（TOP 2A）在原发性阿霉素治疗中的预测作用。方法：232例可手术乳腺癌患者在手术前接受阿霉素治疗。前瞻性评估ER、PgR、分级、Ki-67和HER-2状态。免疫组化检测HER-2过表达;发色原位杂交检测HER-2、TOP 2A和17号染色体着丝粒基因拷贝数。通过乳房X线摄影评估临床缓解。病理反应进行了评估，肿瘤的百分比取代化疗的变化，由于chemotherapy.Results：HER-2扩增与临床反应（p = 0.04）。ER、PgR阴性、Ki-67和HER-2高扩增与病理反应显著相关（p < 0.05）。HER-2和TOP 2A共扩增的肿瘤显示较高的病理变化百分比（p = 0.6）。然而，在多变量分析的完全病理反应，ER阴性和高Ki-67指数是唯一的参数，保持统计significant.Conclusion：HER 2和拓扑异构酶热扩增未能显示与阿霉素的病理反应，而ER阴性和高增殖率预测完全病理反应，这一制度。(c)2006爱思唯尔有限公司保留所有权利。
Aim: To study the predictive role of HER-2 and Topoisomerase II alpha (TOP2A) in response to primary doxorubicin.Methods: Two hundred and thirty-two patients with operable breast cancer were treated with doxorubicin prior to surgery. ER, PgR, grade, Ki-67 and HER-2 status were prospectively assessed. HER-2 overexpression was evaluated with immunohistochemistry; positive cases were then studied for gene copy number of HER-2, TOP2A and chromosome 17 centromere by chromogenic in situ hybridisation. Clinical response was assessed by mammography. Pathological response was evaluated as the percentage of tumour replaced by changes due to chemotherapy.Results: HER-2 amplification was associated with clinical response (p = 0.04). ER and PgR negativity, high Ki-67 and HER-2 amplification significantly correlated to pathological response (p < 0.05). Tumours with coamplification of HER-2 and TOP2A showed a higher percentage of pathological changes (p = 0.6). However, in the multivariate analysis for complete pathological response, ER negativity and high Ki-67 index were the only parameters that maintained statistical significance.Conclusion: HER2 and Topoisomerase Hot amplification failed to show an association with pathological response to doxorubicin, whereas ER negativity and a high proliferation rate were predictive of complete pathological response to this regime. (c) 2006 Elsevier Ltd. All rights reserved.